LivaNova Raises 2026 Adjusted Diluted EPS Range After 10% Revenue Growth

The medical technology company lifted its constant-currency revenue target to 9%-10% and maintained its adjusted free cash flow forecast at $140 million-$160 million.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.